Anti-Mouse CD153 – Purified in vivo GOLD™ Functional Grade

The rat anti-mouse CD30L monoclonal antibody clone RM153 is commonly used in vivo in mice to block or deplete CD30L^+^ cells, thereby interfering with CD30/CD30L interaction, which is central to multiple immune processes.

Key in vivo applications in mice include:

• Prevention or delay of autoimmune diabetes: RM153 treatment in young non-obese diabetic (NOD) mice prevents or delays spontaneous development of type 1 diabetes.
• Suppression of diabetes transfer: RM153 can inhibit the transfer of diabetes from NOD splenocytes or islet-specific cell lines into NOD-SCID recipients, showing blockade of pathogenic mechanisms.
• Modulation of graft-versus-host disease (GVHD): RM153 prolongs survival in CD4^+^ T-cell-mediated lethal GVHD mouse models, potentially by affecting regulatory T cell (Treg)-mediated immune protection or skin allograft rejection.
• Regulation of memory T cell responses: RM153 is used to study suppression of pathogenic memory T cells and the critical role of CD30/CD30L signaling in memory T cell regulation.
• Studies of infection and antibacterial immunity: In C57BL/6 mice infected with Mycobacterium avium, RM153 treatment alters bacterial burden over time, implicating a role for CD30L in controlling chronic infection.
• Cell depletion: The antibody can deplete CD30L^+^ (CD153^+^) cells in vivo, especially in mice engineered to overexpress CD30L; depletion may contribute to the observed in vivo effects.

Most of these applications rely on RM153's ability to block CD30/CD30L interaction or deplete CD30L^+^ cells, thereby modulating immune responses in disease models such as autoimmunity, transplantation, and infection.

Additional commonly cited experimental uses (not limited to in vivo settings) include flow cytometric analysis, immunoprecipitation, and immunohistochemistry for detecting CD153 (CD30L) expression.

In summary, clone RM153 is applied in vivo primarily for mechanistic studies of immune regulation, autoimmune disease models, transplantation immunity, and cell depletion, exploiting its specificity for mouse CD30L (CD153).

Commonly used antibodies or proteins in conjunction with RM153 (an anti-mouse CD153 antibody) are those that mark T cell activation, costimulation, and differentiation, as well as their interacting receptor CD30:

• Anti-CD3: RM153 studies often use anti-CD3 to stimulate T cell activation, as CD3 ligation induces T cell receptor signaling.
• Anti-CD28: Frequently combined with anti-CD3 to provide costimulatory signals for robust T cell activation. CD28 stimulation is important for the upregulation of both CD30 and CD153.
• Anti-CD4: Used to identify CD4+ T cells, which have been shown to express CD153 after activation.
• Anti-CD30: Since CD153 is the ligand for CD30, antibodies against CD30 are commonly used in functional studies to examine the receptor–ligand interaction and downstream effects.
• Anti-CD8: Often used in panels to separate CD8+ vs. CD4+ T cell populations, since expression patterns of CD30 and CD153 can differ.
• Th1/Th2 markers (e.g., IFN-γ, IL-4, CD45RO, IL4R): To define the subset or activation state of T cells expressing CD30 or CD153.
• Viability dyes and isotype controls: Standard in flow cytometry studies to ensure accuracy and specificity.

These combinations are particularly prevalent in studies characterizing T cell activation, costimulation, and CD30/CD153 functional interactions. RM153 is often used to block or detect CD153 in the context of these multiparameter flow cytometry panels or functional assays.

In summary, key antibodies or proteins commonly used with RM153 include anti-CD3, anti-CD28, anti-CD4, anti-CD8, anti-CD30, and various cytokine or subset-defining antibodies that help dissect immune cell phenotypes and interactions.

Overview of Clone RM153

Clone RM153 is a commercially available rat anti-mouse CD30 ligand (CD153 or CD30L) monoclonal antibody (isotype IgG2b). It is used primarily in research to study the biology of CD30L and its role in immune responses, especially in mice.

Key Findings from Scientific Literature

Depletion of CD30L-Expressing Cells
RM153 has been demonstrated to effectively deplete CD30L-expressing cells in vivo. In transgenic mice where CD30L is widely expressed on T cells, a single injection of RM153 (500 μg) led to significant depletion of these cells within 3–4 days. This effect is likely due to antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated lysis, rather than simple blockade of CD30-CD30L interactions. Notably, not all anti-CD30L antibodies have this depleting effect; for example, another clone (M15, rat IgG2a) was found to be non-depleting or weakly depleting in the same model.

Impact on Cognitive Function in Aging
Recent studies used RM153 to explore the role of CD30L-expressing T cells in aging. Flow cytometry confirmed that RM153 treatment depletes CD30L+ CD4+ T cells in aged mice. Behavioral assays revealed that while general mobility, stress levels, and spatial learning were unaffected by RM153 treatment, aged mice showed impaired spatial memory and novel object recognition following depletion of these cells. This suggests that CD30L-expressing T cells play a protective role in maintaining cognitive function during aging.

Mechanism of Action
The primary proposed mechanism of RM153 is in vivo depletion of CD30L+ cells, rather than simply blocking CD30-CD30L interactions. However, in normal mice (where CD30L is expressed only transiently or on small cell subsets), the ability to deplete may be more limited compared to transgenic models with high, constitutive expression.

Applications and Specificity
RM153 is widely used in flow cytometry and functional studies targeting mouse CD30L. Its specificity and performance have been validated in multiple experimental settings, making it a standard tool for investigating CD30L biology.

Summary Table of Key Findings

Conclusion

Clone RM153 is a valuable reagent for studying CD30L biology in mice, particularly for its ability to deplete CD30L-expressing cells in vivo. Its use has provided evidence that these cells are important for cognitive function in aging, beyond their established roles in humoral immunity and inflammation. The antibody’s effectiveness depends on the expression level of CD30L in the target tissue, with more robust effects seen in models of high, constitutive expression.

Overview of Clone RM153 and Its Use

Clone RM153 is a monoclonal antibody targeting mouse CD153 (also known as CD30 ligand, CD30L). It has been studied primarily in the context of autoimmune diseases, such as type 1 diabetes in non-obese diabetic (NOD) mice.

Dosing Regimens in Published Studies

NOD Mouse Model (Type 1 Diabetes Prevention):

• Dose: 500 μg (micrograms) per injection.
• Route: Intraperitoneal (i.p.) injection.
• Frequency: Twice a week.
• Duration: Either from 2–10 weeks of age or from 4–10 weeks of age.
• Outcome: Significant reduction in spontaneous diabetes incidence compared to control IgG-treated mice, with notable effects on insulitis scores.

This regimen demonstrates efficacy in preventing diabetes onset in NOD mice when administered during critical developmental windows.

Other Mouse Models and Regimens

The available literature does not provide dosing information for RM153 in other mouse models or for different experimental endpoints (e.g., immunological studies in C57BL/6 or BALB/c mice). Most references to RM153 focus on its production, use in flow cytometry or other in vitro settings (e.g., ≤0.5 μg per test), which are not relevant for in vivo dosing.

There is no evidence in the provided search results of RM153 being used for chronic disease, cancer, aging, or other models, nor are there variations in dose, route, or frequency beyond the NOD diabetes prevention study.

General Considerations for Monoclonal Antibody Dosing in Mice

While not specific to RM153, monoclonal antibody dosing in mice can vary widely depending on the model, endpoint, and antibody properties. Typical in vivo doses for therapeutic mAbs in mice range from 1–20 mg/kg, often given i.p. or intravenously (i.v.), and frequency can vary from a single dose to weekly or bi-weekly administrations. However, these are general guidelines and do not apply to RM153 unless specifically validated in those contexts.

Summary Table: RM153 Dosing Across Mouse Models

Conclusion

Published dosing regimens of clone RM153 are limited to the NOD mouse model for type 1 diabetes prevention, using 500 μg injected intraperitoneally twice weekly during specific developmental periods. There is no evidence in the available literature of RM153 being dosed differently in other mouse models. For different experimental contexts, researchers would need to empirically determine appropriate regimens, as no established protocols exist outside the NOD diabetes setting.